
    
      A dose escalating study to determine the tolerability and pharmacokinetics (PK) of a
      supra-therapeutic dose of Androxal, up to 250 mg, in healthy adult male subjects as the dose
      to be investigated in a thorough QT interval/corrected QT interval (QT/QTc) study.
    
  